Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Urothelial, Prostate, and Kidney Cancer: CCO Independent Conference Highlights of the 2021 Genitourinary Cancers Symposium

Robert Motzer, MD
Daniel P. Petrylak, MD
Released: March 26, 2021
Back Next

References

  1. Bajorin DF, Witjes JA, Gschwend J, et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 391.
  2. Powles T, Rosenberg JE, Sonpavde G, et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 393.
  3. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;[Epub ahead of print].
  4. Balar AV, McGregor AM, Rosenberg JE, et al. EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 394.
  5. Kolinsky MP, Gravis G, Mourey L, et al. KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Presented at: 2020 Genitourinary Cancer Symposium; February 13-15, 2020. Abstract 103.
  6. Appleman LJ, Kolinsky MP, Berry WR, et al. KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 10.
  7. Mezynski J, Pezaro C, Bianchini D, et al. Antitumor activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943-2947.
  8. Fizazi K, Mella PG, Castellano D, et al. CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 12.
  9. Morris M, Heller G, Bryce AH, et al. Alliance A031201: a phase III trial of enzalutamide (ENZ) vs enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37(suppl 15):5008.
  10. Rathkopf DE, Efstathiou E, Attard G, et al. Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 9.
  11. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408-1418.
  12. Feng FY, Aguilar-Bonavides C, Lucas J, et al. Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC). Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 8.
  13. Motzer RJ, Porta C, Eto M, et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 269.
  14. Powles T, Plimack ER, Soulieres D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563-1573.
  15. Plimack ER, Powles T, Bedke J, et al. Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 327.
  16. Motzer RJ, Rini BI, McDemott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370-1385.
  17. Motzer RJ, Robbins PB, Powles T, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020;26:1733-1741.
  18. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829-841.
  19. Pal SK, Puente J, Hen DYC, et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 307.
  20. Bergerot CD, Rha SY, Pal SK, et al. 2021. Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 314.
  21. Choueiri TK, Plimack ER, Bauer TM, et al. Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). Presented at: 2020 Genitourinary Cancer Symposium; February 13-15, 2020. Abstract 611.
  22. Bauer TM, Choueiri TK, Papadopoulos KP, et al. The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 273.
  23. Choueiri TK, Bauer TM, McDermott DF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 272.
  24. Pal SK, Tangen C, Thompson IM, et al. Sunitinib versus cabozantinib, crizotinib, or savolitinib in metastatic papillary renal cell carcinoma (pRCC): results from the randomized phase II SWOG 1500 study. Presented at: 2021 Genitourinary Cancer Symposium; February 11-13, 2021. Abstract 270.
  25. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open-label, phase 3 trial. Lancet Oncol. 2016;17:917-927.
  26. Choueiri TK, Halabi S, Ben L, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591-597.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Astellas
Eisai
Merck Sharp & Dohme Corp.
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings